Navigation Links
Amgen, Hospira and Sandoz Named Among Top Pharmaceutical Companies with Greatest Biosimilar Drug Potential in United States
Date:5/14/2013

PHILADELPHIA, May 14, 2013 /PRNewswire/ -- The IP & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today announced the release of a life sciences report, "An Outlook on U.S. Biosimilar Competition," providing a comprehensive view of the challenges facing companies entering the United States biosimilar drug market and key players predicted to break into this developing pharmaceutical space.

While the U.S. continues to take steps toward entering the global biosimilar market, it lags behind other nations in this space. The report compares U.S. and EU regulations to underscore the significant differences between these regions and explore ways the U.S. can compete more effectively, in addition to reviewing emerging regulatory developments in India and China. It also identifies potential leaders of the U.S. market, including Amgen, Hospira and Sandoz, among the top three pharmaceutical companies with the most potential to dominate the early stages of biosimilar medications entering the U.S.

Biologic medicines, including biosimilars, are developed using living organisms instead of synthesized chemical compounds and are known to effectively treat a range of conditions including rheumatoid arthritis, metastatic breast cancer, non-Hodgkin lymphoma and anemia. Innovative biologic treatments can cost tens of thousands of dollars per year. Competition from biosimilar therapies will help to lower the cost of these expensive treatments, thus helping to reduce healthcare costs and increase patient access.

"This report is a prime example of the insight that can be gleaned by our internal experts using our high quality, curated life sciences data," said Jon Brett-Harris , managing director, Thomson Reuters Life Sciences.  "Our goal is to provide cutting-edge information and solutions to support our clients making confident decisions related to drug discovery, development and delivery."

"An Outlook on U.S. Biosimilar Competition" was created by Thomson Reuters experts in generic drug and API intelligence. The team utilized Newport Premium, the industry's leading tool for identifying and evaluating generic drug development and licensing opportunities, to compile the report.

View "An Outlook on U.S. Biosimilar Competition."

Learn more about Thomson Reuters Generic and API Intelligence and Newport Premium.

Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minn., Thomson Reuters employs approximately 60,000 people and operates in over 100 countries. Thomson Reuters shares are listed on the Toronto and New York Stock Exchanges. For more information, go to www.thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira dévoile sa stratégie appareil mondiale
2. Hospira enthüllt weltweite Gerätestrategie
3. Hospira revela estrategia global para sus dispositivos
4. Hospira revela estratégia global para dispositivos
5. Hospira Reports First-Quarter 2013 Results
6. Hospira Unveils Global Device Strategy
7. Hospira Names Matthew R. Stober Senior Vice President of Operations
8. Hospira to Host Conference Call for First-Quarter 2013 Results
9. Hospira Announces Executive Changes
10. Hospira Reports Fourth-Quarter and Full-Year 2012 Results
11. Hospira to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... VIEJO, Calif. , Feb. 12, 2016  Sequent ... enrollment in a study to evaluate the safety and ... for the treatment of ruptured intracranial aneurysms.  Prof ... University Hospital, in Paris, France ... first patient. France and ...
(Date:2/12/2016)... INDIANAPOLIS , Feb. 12, 2016  Eli Lilly and ... High Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent ... in the UK, France , ... instructions to dilute the product only with dextrose solution.  ... of 2015, the UK Court of Appeal held that Lilly,s ...
(Date:2/12/2016)... , 12 februari 2016 ... een toonaangevende leverancier van productie en ontwikkeling ... industrieën, kondigt vandaag een uitbreiding aan van ... haar locatie in Charleston, SC ... geleid tot meerdere recente investeringen. ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... ... Pittsburgh metro area, celebrates the beginning of the latest charity campaign in their ... skills through art. Donations to this worthy cause are currently being accepted at: ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... “Revolutionizing Cancer Care.” , The print component of “Revolutionizing Cancer Care” ... Pittsburgh/Cleveland, New York, Washington DC/Baltimore, and Seattle, with a circulation of approximately 250,000 ...
(Date:2/12/2016)... ... , ... A lot has been reported about the fitness routines of United ... and wellness resources most Americans could ever dream of having at their disposal. However, ... frenetic as the U.S. President. , In honor of President’s Day on Feb. ...
(Date:2/12/2016)... ... February 12, 2016 , ... Basketball is a game for everyone, not just ... PoppersTM series, sign language translation is featured in the top right of the screen. ... PoppersTM lessons has a sign language translator to teach kids the game and how ...
(Date:2/11/2016)... ... February 11, 2016 , ... “ HEALING MIND : Five Steps ... Mind” (published by Balboa Press) teaches readers how to become their own therapist. Providing ... author Janice McDermott, M.Ed., LCSW, offers an understanding of how to heal one’s inner ...
Breaking Medicine News(10 mins):